AMG 334, the First Potent and Selective Human Monoclonal Antibody Antagonist Against the CGRP Receptor

LBO2

  • Shi, L.
  • Rao, S.
  • King, C.
  • Sun, H.
  • Zhu, D.
  • Lehto, S.
  • Wild, K.
  • Immke, D.
  • Xu, C.

  • 1Neuroscience, Amgen, Thousand Oaks, CA, USA;

    2Therapeutic Discovery, Amgen, Burnaby, BC, Canada.

Headache 54(8):p 1417-1418, September 2014.
Copyright © 2014 John Wiley & Sons, Ltd